These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38605325)

  • 1. HIV viral suppression and risk of viral rebound in patients on antiretroviral therapy: a two- year retrospective cohort study in Northern Tanzania.
    Kahabuka MS; Woldeamanuel Y; Mbelele PM; Mpolya EA; Mpagama SG; Kessy JP; Manyazewal T
    BMC Infect Dis; 2024 Apr; 24(1):390. PubMed ID: 38605325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
    Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
    J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
    Shoko C; Chikobvu D; Bessong PO
    S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral load suppression after intensive adherence counselling among adult people living with HIV at Kiswa health centre, Kampala: a retrospective cohort study. Secondary data analysis.
    Nakaye C; Mukiza N; Mawanda D; Kataike H; Kaganzi H; Ahimbisibwe GM; Businge GB; Kyambadde RC; Nakalega R
    AIDS Res Ther; 2023 Mar; 20(1):18. PubMed ID: 36998004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
    Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
    Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of viral load suppression failure among HIV adults on ARV attending health care facilities: a retrospective study in Tanga region, Tanzania.
    Mboggo E; Mtisi E; Mushy SE; Mkawe S; Ngalesoni F; Muya A; Kilimba E; Kamugumya D; Mlay BS
    BMC Infect Dis; 2024 Mar; 24(1):312. PubMed ID: 38486174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
    Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
    Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low-level viraemia in Uganda.
    Nanyeenya N; Nakanjako D; Makumbi F; Nakigozi G; Nalugoda F; Kigozi G; Nasuuna E; Kibira SPS; Nabadda S; Kiyaga C; Huzaifah M; Kiwanuka N
    HIV Med; 2024 Feb; 25(2):245-253. PubMed ID: 37853605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda.
    Ssebunya R; Wanyenze RK; Lukolyo H; Mutto M; Kisitu G; Amuge P; Maganda A; Kekitiinwa A
    BMC Infect Dis; 2017 Jun; 17(1):439. PubMed ID: 28629459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study.
    Lewis L; Sookrajh Y; van der Molen J; Khubone T; Sosibo P; Maraj M; van Heerden R; Little F; Kassanjee R; Garrett N; Dorward J
    J Int AIDS Soc; 2023 Sep; 26(9):e26164. PubMed ID: 37767825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between low-level viraemia and subsequent viral non-suppression among people living with HIV/AIDS on antiretroviral therapy in Uganda.
    Nanyeenya N; Chang LW; Kiwanuka N; Nasuuna E; Nakanjako D; Nakigozi G; Kibira SPS; Nabadda S; Kiyaga C; Makumbi F
    PLoS One; 2023; 18(1):e0279479. PubMed ID: 36638086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda.
    Ndikabona G; Alege JB; Kirirabwa NS; Kimuli D
    BMC Public Health; 2021 Dec; 21(1):2294. PubMed ID: 34922502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy programme outcomes at Senkatana antiretroviral therapy clinic, Lesotho: a four-year retrospective cohort study.
    Kabuya M; Musekiwa A; Takuva S; Thabane L; Mbuagbaw L
    Pan Afr Med J; 2023; 46():74. PubMed ID: 38282767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with viral load non-suppression in people living with HIV on ART in Nigeria: cross-sectional analysis from 2017 to 2021.
    Tomescu S; Crompton T; Adebayo J; Akpan F; Dauda DS; Allen Z; Ondura EO; Wose Kinge C; Chasela C; Pisa P
    BMJ Open; 2023 May; 13(5):e065950. PubMed ID: 37169497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of routine viral load testing among people living with HIV and its implementation challenges in Yangon region of Myanmar: a mixed-methods study.
    Thinn KK; Thekkur P; Kyaw NTT; Aye NS; Zaw TM; Soan P; Hone S; Oo HN
    BMJ Open; 2019 Dec; 9(12):e032678. PubMed ID: 31796489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.
    O'Connor J; Smith C; Lampe FC; Johnson MA; Chadwick DR; Nelson M; Dunn D; Winston A; Post FA; Sabin C; Phillips AN;
    Lancet HIV; 2017 Jul; 4(7):e295-e302. PubMed ID: 28479492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to viral load suppression among adolescents living with HIV on anti-retroviral therapy: a retrospective study in Tanga, Tanzania.
    Mushy SE; Mtisi E; Mkawe S; Mboggo E; Ndega J; Yahya-Malima KI; Kamugunya D; Kilimba ES; Mlay BS; Muya A; Ngalesoni F
    AIDS Res Ther; 2024 May; 21(1):35. PubMed ID: 38778318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Viral load in HIV-infected children on high activity antiretroviral therapy].
    Resino S; Bellón JM; León JA; Resino R; Muñoz-Fernández MA;
    Med Clin (Barc); 2007 Jan; 128(2):49-51. PubMed ID: 17266901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the COVID-19 pandemic on HIV service delivery and viral suppression: Findings from the SHARP program in Northern Nigeria.
    Mugo C; Adedokun O; Alo OD; Ezeokafor N; Adeyemi S; Kpamor Z; Madueke L; James E; Adebajo SB; Semo BW
    PLoS One; 2024; 19(4):e0300335. PubMed ID: 38564514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.